ArticleIranian journal of microbiology2026
Evaluation of galactomannan assay in diagnosing invasive aspergillosis.
Article in Iranian journal of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: In most laboratories, diagnosis of invasive aspergillosis (IA) depends on culture and histopathological examination of the involved tissues. Galactomannan (GM) is a polysaccharide antigen detectable in body fluids and represents an ideal assay for diagnosing invasive pulmonary aspergillosis. The main objectives of this study were to estimate the proportion of patients with proven, probable, and possible aspergillosis and to compare different diagnostic methods. Materials and Methods: Samples for culture, microscopy, and GM assay were taken from a total of 60 patients. The enrolled patients were divided into proven, probable, and possible aspergillosis groups. Results: Among the 60 patients in the study, there were 9 (15%) cases of probable aspergillosis. galactomannan assay was positive in 19 patients. Galactomannan assay had a higher sensitivity (66.7%) when compared to other fungal assays for diagnosing probable aspergillosis. Conclusion: Diagnosing invasive aspergillosis is extremely challenging, and biomarkers such as galactomannan assay are important for early diagnosis. Raising the cutoff to >1 can eliminate false-positive results associated with the GM assay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.